Show simple item record

dc.contributor.authorAnderson, Heather
dc.contributor.authorPrendiville, Joseph A
dc.contributor.authorThatcher, Nick
dc.contributor.authorRadford, John A
dc.contributor.authorSwindell, Ric
dc.date.accessioned2010-06-10T08:35:39Z
dc.date.available2010-06-10T08:35:39Z
dc.date.issued1991
dc.identifier.citationA randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. 1991, 117 Suppl 4:S139-40 J. Cancer Res. Clin. Oncol.en
dc.identifier.issn0171-5216
dc.identifier.pmid1665490
dc.identifier.doi10.1007/BF01613219
dc.identifier.urihttp://hdl.handle.net/10541/104582
dc.description.abstract159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdministration, Oral
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshDoxorubicin
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshInfusions, Intravenous
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshSurvival Analysis
dc.titleA randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalJournal of Cancer Research and Clinical Oncologyen
html.description.abstract159 "poor risk" patients with previously untreated small cell lung cancer were entered into a randomised study of intravenous bolus versus continuous infusion chemotherapy with doxorubicin on weeks 1, 3, 5 and ifosfamide with mesna on weeks 2, 4, 6. Oral etoposide was given on days 1-5, 15-19, and 29-33. There was no difference in response rate or survival. However, patients treated with continuous infusion therapy had significantly less haematological toxicity (P = 0.0007), and less nausea and vomiting (P = 0.03).


This item appears in the following Collection(s)

Show simple item record